Joanne Beck
Director/Board Member at ASTRIA THERAPEUTICS, INC.
Net worth: - $ as of 2024-06-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Ford | M | 50 | 9 years | |
| Jill Milne | M | 56 | 16 years | |
| Marc Dunoyer | M | 71 |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Charles Rowland | M | 65 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Bobby Gaspar | M | 60 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 9 years |
| Hubert Allen | M | 58 | 18 years | |
| Alicia Secor | F | 62 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| David Elkins | M | 55 | 6 years | |
| Scott House | M | - | 34 years | |
| Kathryn Collins | F | - | 25 years | |
| John McCoy | M | 54 | 6 years | |
| Ken Bate | M | 73 | 10 years | |
| Simone Song | F | 59 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 7 years |
| James Geraghty | M | 69 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Noah Clauser | M | 51 | 13 years | |
| Jon Ellis | M | 57 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Andrea Matthews | F | 42 | 10 years | |
| Frank Thomas | M | 54 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Sally Blount | M | 62 | 13 years | |
| Katherine Reynolds Kelly | F | 48 | 5 years | |
| Paola Gonzalez | F | 52 | 3 years | |
| Claire Babineaux-Fontenot | F | 59 | 2 years | |
| Michelle Kumbier | F | 57 | 6 years | |
| Hugh Cole | M | 59 | 5 years | |
| P. Joseph Campisi | M | - | 5 years | |
| Scott Leinenweber | M | - | 27 years | |
| Philip Boudreau | M | 51 | 27 years | |
| Frederick Callori | M | 56 | 3 years | |
| Darren McDew | M | 63 | 5 years | |
| Daniel Starks | M | 69 | 7 years | |
| Michael O'Grady | M | 58 | 1 years | |
| Rajeev Venkayya | M | - |
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Jonathan Violin | M | 48 | 3 years | |
| Melissa Brotz | F | - | - | |
| Michael Kishbauch | M | 75 | 8 years | |
| Matt Roden | M | 53 | 5 years | |
| John Stratton | M | 63 | 7 years | |
| Gregg Lapointe | M | 65 | 5 years | |
| Randel Woodgrift | M | 62 | 12 years | |
| Robert Alpern | M | 73 | 16 years | |
| Mary Moreland | F | 57 | 13 years | |
| Michael Roman | M | 64 | 3 years | |
| Nancy McKinstry | F | 65 | 13 years | |
| Karen Chayavirabood | F | - | - | |
| Jim Leffelman | M | - | - | |
| Ann Li Lee | M | 63 | 6 years | |
| Stephen Knight | M | 63 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Kate Dyer | F | - | 4 years | |
| Christopher Morabito | M | 54 | 2 years | |
| John Maraganore | M | 60 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Andrea Wainer | F | - | 27 years | |
| John M. Capek | M | 62 | 18 years | |
| Vincent Ossipow | M | 55 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Peter Honig | M | 67 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Fulvio Mavilio | M | - | 2 years | |
| Otello Stampacchia | M | 55 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Yasuo Fujii | M | - | - | |
| Abdul Mullick | M | - | - | |
| Daniel Gesua Sive Salvadori | M | - | - | |
| Lisa Earnhardt | F | 54 | 5 years | |
| Jeffrey Galik | M | - | 5 years | |
| Gene Huang | M | - | - | |
| Takeyoshi Yamashita | M | 62 | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Rothera | M | 61 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | 3 years |
| Mark Alles | M | 64 | 15 years | |
| Jacqualyn Fouse | M | 62 | 7 years | |
| Deirdre Cunnane | F | 59 | 4 years | |
| Robert Hugin | M | 69 | 19 years | |
| Jonathan Biller | M | 61 | 8 years | |
| Nicolas Koebel | M | 52 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 7 years |
| Timothy J. Smith | M | - | - | |
| Peter Kellogg | M | 67 | 5 years | |
| Scott Smith | M | 61 | 10 years | |
| Thomas Daniel | M | 70 | 10 years | |
| Anne Dupraz-Poiseau | M | - | 6 years | |
| Andrea Spezzi | M | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 years |
| Thomas Perone | M | 59 | 12 years | |
| Brendan Delaney | M | 49 | 6 years | |
| Jacquelyn Sumer | F | 46 | 1 years | |
| John Curnutte | M | 72 | 5 years | |
| Alexander Pasteur | M | 54 | - | |
| Jay Backstrom | M | 69 | 11 years | |
| Rupert Vessey | M | 59 | 4 years | |
| Carrie Cox | F | 66 | 10 years | |
| Michael Ross | M | 75 | 9 years | |
| Steven Altschuler | M | 70 | 4 years | |
| Michael Friedman | M | 80 | 8 years | |
| Jean George | F | 66 | 9 years | |
| Michael Bonney | M | 65 | 4 years | |
| Elise T. Wang | F | 64 | - | |
| James J. Loughlin | M | 81 | 12 years | |
| Richard W. Barker | M | 75 | 7 years | |
| Burt Adelman | M | 71 | 5 years | |
| Michael D. Casey | M | 78 | 17 years | |
| Ernest Mario | M | 85 | 12 years | |
| Gilla Kaplan | M | 76 | 20 years | |
| John Weiland | M | 68 | 1 years | |
| Patricia Hemingway Hall | F | 71 | 1 years | |
| Craig T. Basson | M | - |
Boston Pharmaceuticals, Inc.
 Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Boston Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that leverages a drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The company was founded by Robert Armstrong and Chris Viehbacher and is headquartered in Cambridge, MA. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 80 | 80.81% |
| United Kingdom | 20 | 20.20% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joanne Beck
- Personal Network
